Tag Archive | "Valeant"

Valeant ups offer and secures Salix; Endo withdraws

Tags: , ,

Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00 per share Read the full story

Valeant acquires Salix Pharma for $14.5 billion

Tags: , , ,

Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix Read the full story

M&A news: who will win the bidding race?

Tags: , , , ,

M&A news: The Canadian pharma company Valeant Pharmaceuticals is rumoured to be raising money to make a bid for specialty drugmaker Salix Pharmaceuticals, according to Bloomberg, which cites people familiar with the matter.

Read the full story

Valeant Pharmaceuticals raises $1 billion in private financing

Tags: , ,

Big pharma, Valeant Pharmaceuticals International, has completed the private placement financing of senior unsecured notes due 2023, for gross proceeds of USD1 billion. Read the full story

Asset purchase agreement for dermatology product portfolio

Tags: ,

Valeant Canada has completed the acquisition of Valeo Pharma's dermatology product portfolio and several specialty products. Read the full story

Valeant extends the acquisition of Allergan

Tags: , ,

Valeant Pharmaceuticals has extended the acquisition period for Allergan. Read the full story

ECR Pharma is acquired by Valeant

Tags: , , ,

Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. Read the full story


Tags: ,

Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada Read the full story

Valeant plans for a hostile takeover of Allergan

Tags: , ,

Valeant Pharmaceuticals and Pershing Square plan to approach the shareholders of Allergan for a hostile takeover. Read the full story

Valeant sells its dermatology products for $1.4 billion

Tags: , , ,

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Read the full story